ImmunoGen

ImmunoGen, Inc. is a clinical-stage biotechnology company based in Waltham, Massachusetts, specializing in the development of antibody-drug conjugate (ADC) therapies for cancer treatment. The company's lead product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha currently in Phase III trials for platinum-resistant ovarian cancer, and IMGN632, which targets CD123 and is being evaluated in Phase I trials for acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Additionally, ImmunoGen is advancing several other investigational therapies, including those in collaboration with MacroGenics. The company employs its proprietary Targeted Antibody Payload technology to deliver cytotoxic agents directly to cancer cells, enhancing treatment efficacy while minimizing damage to healthy tissue. ImmunoGen has established partnerships with various pharmaceutical companies, including Roche, Amgen, and Sanofi, to further its research and development efforts in the oncology field.